icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
S68d1hVZGe1kwgqC